New Ways To Develop Medecines
Landmark BioVentures (LBV) is a global hub-and-spoke biotech company that creates new ways to develop medicines serving patients who suffer from life-threatening diseases.
Created in 2021 and headquartered in Basel (Switzerland), LBV has already built from scratch a nexus of biotech companies developing first-in-class therapeutics against fibrotic, neovascular and/or neoplastic disorders.
Our unique model combines smart use of capital, cross-fertilization, exponential value creation and diversification. LBV team is composed of seasoned multi-disciplinary drug developers and deal makers with proven record.
Landmark Bioventures Unique Model
Completely building Biotech Start-ups
from scratch in a lean and cost-effective way
Creating a diversified nexus of new ventures with a focus on fibrotic neovascular and/or neoplastic disorders
Developing first-in-class medecines combining cross-fertlization and exponential value creation
Diversified Nexus of New Biotech Ventures
Founders & Partners
Samson Fung
Co-Founder & CMO
-
30+ years of experience in Biotech and Pharma
-
Physician by training in oncology and hematology
-
Former CEO of Volvox Therapeutics
-
Expert in clinical development, medical affairs market access
-
Spent 15+ years in pharma including Roche, Novartis, Novo Nordisk and Astra Zeneca
Bernouillistrasse 20
Basel CH-4056
Switzerland